First Bancorp Inc ME Has $226,000 Stake in Amgen Inc. (NASDAQ:AMGN)

First Bancorp Inc ME reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 7.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 702 shares of the medical research company’s stock after selling 60 shares during the period. First Bancorp Inc ME’s holdings in Amgen were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Strategic Financial Concepts LLC bought a new stake in shares of Amgen during the second quarter worth $26,000. Hershey Financial Advisers LLC bought a new stake in Amgen during the 2nd quarter worth $30,000. nVerses Capital LLC acquired a new position in Amgen in the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen in the second quarter valued at about $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen during the third quarter valued at about $36,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Barclays upped their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Cantor Fitzgerald initiated coverage on shares of Amgen in a report on Friday, September 27th. They set an “overweight” rating and a $405.00 price target on the stock. TD Cowen increased their price objective on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $329.48.

Amgen Stock Up 0.1 %

Shares of AMGN traded up $0.33 during trading hours on Friday, hitting $321.66. The stock had a trading volume of 1,552,126 shares, compared to its average volume of 2,447,665. The firm has a 50 day simple moving average of $326.07 and a 200-day simple moving average of $311.90. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The firm has a market capitalization of $172.55 billion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the business posted $5.00 EPS. The company’s revenue was up 20.1% on a year-over-year basis. Sell-side analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.80%. Amgen’s dividend payout ratio is presently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.